Out of 6,400+ total scientific abstracts, the American Society of Clinical Oncology selected an NCODA abstract for online publication for the 2018 ASCO Annual Meeting. Through the abstract titled: Cost avoidance through the medically integrated dispensary (MID) for oral chemotherapy: Utilizing the NCODA cost avoidance and waste tracker, we were able to present collective intervention outcome data that resulted in the cost avoidance in the millions of dollars. We would like to thank all the participating NCODA members who have helped provide a stronger voice and another milestone for our collaborative mission to improve oral oncology care at Medically Integrated Dispensing Organizations. It is through our members that NCODA can further advocate the financial influence and positive change that MID Organizations can provide.

Read the entire abstract here

Read More

Written By: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch
Download Here

Description Venetoclax is as selective inhibitor of B cell lymphoma-2 (BCL-2). Inhibition of BCL-2 by venetoclax results in cytotoxic activity in tumor cells that overexpress BCL-2 by restoring apoptosis. Venetoclax is indicated in Acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL) and small lymphocytic leukemia (SLL) in patients with or without chromosome 17p deletion.  During the ramp-up phase, patients are titrated on venetoclax and assigned a risk category based on tumor burden and potential for developing Tumor Lysis Syndrome (TLS).  These risk stratifications create special challenges for the dispensing of venetoclax.   Some medium-risk and all high-risk patients may require hospital admission during titration; communication between the oncology pharmacist, nurse, lab technicians, hematologist, and the patient will ensure the recommended administration guidelines and lab monitoring are followed to ensure patient safety and best outcomes.

Continue reading Venetoclax Risk Stratification, Dosing, and Dispensing Procedure

Read More
image-title

MISSION STATEMENT

The Mission of HOA is to provide the highest level of quality care in a healing environment for the mind, body and spirit of patients dealing with cancer and blood disorders. Our goal is to offer the highest level, state of the art technology and treatments, while meeting the emotional needs of our patients and their families. Continue reading Hematology Oncology Associates of Central New York

Read More